- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000188
Selegiline in Treatment of Cocaine Dependence - 2
May 26, 2015 updated by: James Cornish, University of Pennsylvania
Selegiline in Treatment of Cocaine Dependence
The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.
Study Overview
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- PDVAMC Treatment Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Please contact site for information.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Retention
|
Cocaine use
|
Cocaine craving
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: James Cornish, M.D., University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1994
Primary Completion (Actual)
October 1, 1995
Study Completion (Actual)
October 1, 1995
Study Registration Dates
First Submitted
September 20, 1999
First Submitted That Met QC Criteria
September 20, 1999
First Posted (Estimate)
September 21, 1999
Study Record Updates
Last Update Posted (Estimate)
May 28, 2015
Last Update Submitted That Met QC Criteria
May 26, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Psychotropic Drugs
- Antidepressive Agents
- Monoamine Oxidase Inhibitors
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Selegiline
Other Study ID Numbers
- NIDA-00144-2
- 3R01DA012268 (U.S. NIH Grant/Contract)
- K20-00144-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine-Related Disorders
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Columbia UniversityNot yet recruitingCocaine Use Disorder | Cocaine Dependence | Cocaine Use | Cocaine Use Disorder, Moderate | Cocaine Use Disorder, Severe
-
Tonix Pharmaceuticals, Inc.National Institute on Drug Abuse (NIDA); PremierNot yet recruitingCocaine Use | Cocaine Abuse | Cocaine Adverse Reaction | Cocaine Intoxication | Cocaine Toxicity
-
Temple UniversityNational Institute on Drug Abuse (NIDA); University of PennsylvaniaCompletedCocaine-Related Disorders | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
University of VirginiaRecruitingCocaine Use Disorder | Cocaine Dependence | Ultrasound | Cocaine AbuseUnited States
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingCocaine Dependence | Cocaine Use | Cocaine Abuse | NeurotropismItaly
-
University Hospital Center of MartiniqueUnknown
Clinical Trials on Selegiline
-
National Institute on Drug Abuse (NIDA)CompletedMarijuana AbuseUnited States
-
Somerset PharmaceuticalsCompleted
-
Somerset PharmaceuticalsCompleted
-
National Institute of Allergy and Infectious Diseases...National Institute of Neurological Disorders and Stroke (NINDS); Neurologic...CompletedHIV Infections | Cognition DisordersUnited States
-
Ludwig-Maximilians - University of MunichCompletedMénière's DiseaseGermany
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Cognitive DisordersUnited States
-
Mood and Anxiety Research, IncCompletedBorderline Personality DisorderUnited States
-
New York State Psychiatric InstituteTerminated
-
Parkinson's Disease and Movement Disorder Center...Bausch Health Americas, Inc.CompletedParkinson's DiseaseUnited States
-
Somerset PharmaceuticalsCompletedMajor DepressionUnited States